Company news: K-V Pharmaceutical and Ther-Rx

Share this article:
In a blow to K-V Pharmaceutical, the FDA said it will not take action against pharmacies that make hydroxyprogesterone caproate, the active ingredient in K-V's recently approved pre-term labor prevention drug Makena. K-V had sent a letter to pharmacists indicating that the agency will no longer allow them to make or compound the injectable drug. “This is not correct,” said FDA in a statement, adding it would not pursue enforcement unless the compounded products are unsafe, of substandard quality or are not compounded according to standards. K-V's branded drug subsidiary Ther-Rx started promoting Makena in March.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.